Posted by Michael Wonder on 24 Mar 2026
Dupixent (dupilumab) approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
24 March 2026 - Bullous pemphigoid is the seventh approved indication for Dupixent in Japan
Regeneron Pharmaceuticals and Sanofi today announced that the MHLW in Japan has approved Dupixent (dupilumab) for the treatment of adults with moderate to severe bullous pemphigoid.
